The issues and the controversies: are we really ready for on-demand use of ICS? Source: Annual Congress 2013 –Inhaled corticosteroids for asthma: on-demand or continuous use? Year: 2013
What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement Source: Eur Respir J, 52 (5) 1801261; 10.1183/13993003.01261-2018 Year: 2018
Opioid use, perhaps a harbinger of worsening COPD? Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020
Respiratory medicines for children: current evidence, unlicensed use and research priorities Source: Eur Respir J 2010; 35: 247-265 Year: 2010
Delivering high value therapies in COPD: the secret is in the marketing Source: Eur Respir J, 53 (4) 1900215; 10.1183/13993003.00215-2019 Year: 2019
Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
The drug costs associated with COPD prescription medicine in Denmark Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012
Pharmacological treatment & current controversies in COPD Source: ERS Course 2019 - Masterclass in airways disease 2019 Year: 2019
What is the scientific and clinical rationale? Triple therapy in COPD patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021
The healthcare burden of non-compliance to pharmacotherapeutic escalation recommendations for COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016
The use of electronic alerts in primary care to identify the over-prescription of short-acting beta2-agonists in people with asthma: a systematic review Source: International Congress 2017 – Primary care management of asthma and COPD Year: 2017
Evolving use of long-term NIV in COPD: Are we getting it right Source: Annual Congress 2013 –Long-term NIV: COPD, sleep, obesity and outcomes Year: 2013
Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009
The future of COPD treatment: what are the difficulties in and barriers to drug development for COPD Source: Annual Congress 2011 - Lancet / ERS symposium - New frontiers in COPD Year: 2011
Effects of pharmacist interventions to inhalation medication adherence and lung functions in COPD patients at one stop service clinic Source: International Congress 2014 – COPD exacerbations Year: 2014
Tele-education in asthma management. What are the benefits? Source: Annual Congress 2012 - Improving education for the healthcare team and patients Year: 2012
Prevention of COPD exacerbations: medications and other controversies Source: ERJ Open Res 2015; 1: 00011-2015 Year: 2015
Optimising COPD prevention: what do the doctors need? Source: Annual Congress 2007 - Smoking and the lung Year: 2007